Inactive Instrument

STAR Pharmaceutical Limited

SRPT

SG1BB3000009

STAR Pharmaceutical Limited Reports Unaudited Consolidated Impairment Results for the Fourth Quarter Ended December 31, 2018

February 27, 2019

STAR Pharmaceutical Limited reported unaudited consolidated impairment results for the fourth quarter ended December 31, 2018. For the quarter, the company reported impairment loss on fixed assets was RMB 1,491,000.

Latest news about STAR Pharmaceutical Limited

Star Pharmaceutical Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	13/19/13	CI
Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical completed the acquisition of remaining 46.8% stake in STAR Pharmaceutical Limited from Li Tak Tai Leada and other shareholders.	07/19/07	CI
STAR Pharmaceutical Limited Announces Change of Registered Office Address	12/19/12	CI
Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical made an offer to acquire remaining 46.8% stake in STAR Pharmaceutical Limited from Li Tak Tai Leada and other shareholders for SGD 9.7 million.	05/19/05	CI
Xu Zhi Bin, Executive Chairman of Board of STAR Pharmaceutical acquired an additional 22.7% stake in STAR Pharmaceutical Limited from Wang Qi for SGD 1.5 million.	05/19/05	CI
Star Pharmaceutical Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	31/19/31	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	31/19/31	CI
STAR Pharmaceutical Limited Provides Group Financial Guidance for the Half Year Ended 30 June 2019	18/19/18	CI
Star Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended March 31, 2019	15/19/15	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	15/19/15	CI
STAR Pharmaceutical Limited's Equity Buyback announced on August 7, 2018, has expired with 616,500 shares, representing 1.33% for SGD 0.09 million.	26/19/26	CI
STAR Pharmaceutical Limited Announces Board Changes	01/19/01	CI
Star Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	27/19/27	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	27/19/27	CI
STAR Pharmaceutical Limited Reports Unaudited Consolidated Impairment Results for the Fourth Quarter Ended December 31, 2018	27/19/27	CI
Star Pharmaceutical Limited Reports Earnings Results for the Third Quarter Ended September 30, 2018	08/18/08	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 7, 2018.	08/18/08	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 31, 2017.	13/18/13	CI
STAR Pharmaceutical Limited Reports Unaudited Group Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	13/18/13	CI
STAR Pharmaceutical Limited commences an Equity Buyback Plan for 4,649,169 shares, representing 10% of its issued share capital, under the authorization approved on April 27, 2018.	07/18/07	CI
STAR Pharmaceutical Limited Reports Un-Audited Group Earnings Results for the First Quarter Ended March 31, 2018	11/18/11	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 31, 2017.	11/18/11	CI
STAR Pharmaceutical Limited's Equity Buyback announced on August 31, 2017, has expired with 118,800 shares, representing 0.25% for SGD 0.03 million.	27/18/27	CI
Tranche Update on STAR Pharmaceutical Limited's Equity Buyback Plan announced on August 31, 2017.	10/18/10	CI
STAR Pharmaceutical Limited Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2017	04/18/04	CI

Chart STAR Pharmaceutical Limited

Duration

Period

More charts

Company Profile

STAR Pharmaceutical Limited is an investment holding company. The principal activities of the subsidiaries are those relating to the development, manufacturing and trading of pharmaceutical products. The Company operates in the development, manufacturing and trading of pharmaceutical products segment. The Company and its subsidiaries are engaged in the manufacture and sale of both western and Traditional Chinese Medicine (TCM)-formulated prescription drugs. The Company's range of pharmaceutical products include antibiotics, cerebrovascular drugs and cardiovascular drugs, and other specialized drugs manufactured in-house in various dosages and administration forms from powder injections, lyophilized powder injections, liquid injections to tablets, capsules and granules. It has approximately 820 distributors to hospitals, clinics and pharmacies. The Company has a manufacturing facility based in Qionghai City, Hainan Province of People's Republic of China.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+22.66%	4.38TCr
OTSUKA HOLDINGS CO., LTD.	+25.56%	2.3TCr
SANDOZ GROUP AG	+18.88%	1.53TCr
CIPLA LIMITED	+9.91%	1.37TCr
ZYDUS LIFESCIENCES LIMITED	+42.38%	1.2TCr
ONO PHARMACEUTICAL CO., LTD.	-7.49%	697.64Cr
THE MEDICINES COMPANY	-0.05%	678.76Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+13.26%	559.02Cr

Generic Pharmaceuticals